Gene editing for hepatitis b: researchers track Long-Term safety
NCT ID NCT07254208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term safety of this gene editing approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 45 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Jun 2040
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.
- Ages
-
19 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participant has received at least 1 dose of PBGENE-HBV investigational product in a prior clinical study 2. Participant, or their legally authorized representative, has provided signed informed consent. Exclusion Criteria: * N/A
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic HBV infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites in 4 countries. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
ICS ARENSIA Exploratory Medicine SRL
Chisinau, Moldova, 2025, Moldova
-
Massachusetts General Hospital/Harvard University
Boston, Massachusetts, 02114, United States
-
New Zealand Clinical Research
Auckland, New Zealand, 1010, New Zealand
-
Queen Mary Hospital, University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.